CRISPR/Cas9 tech and gene editing has emerged as a hot field in biotech, spurring a full slate of startups. Now one of the pioneers in the field has supervised a project that points to a more efficient use of technology in editing T cells.
A global team of scientists working with Johns Hopkins' Jordan Green has developed a new nonviral gene therapy for brain cancer, successfully testing it in the lab in cell lines as well as rat models for the disease. Read more >>
Universities regularly woo top scientists from rival institutions, recruiting not only high-profile individuals but their lab teams as well in the hope of bagging promising science and the millions in federal funding that go along with it. But in a rare confrontation, UC San Diego has sued USC and research scientist Paul Aisen for an alleged conspiracy to purloin data and investigators involved in prominent Alzheimer's research work. Read more >>
POPULAR COMMENT THREADS
A research team at Massachusetts General developed a gene therapy to deliver a protein that demonstrated signs of successfully reining in recurrent ovarian cancer in a mouse model for the disease.
An assistant professor of neurosurgery at The University of Florida (UF) College of Medicine has demonstrated a novel therapeutic strategy to significantly slow the growth of an aggressive brain tumour.
Researchers at the University of Southampton have developed a small molecule which they refer to as "Compound 14" that deceives cells into thinking they have run out of energy--spurring on glucose uptake and increasing metabolism.
Professor Nicholas Tonks and colleagues at Cold Spring Harbor Laboratory say that they've seen a promising response to PTP1B inhibitors in mouse models of Rett syndrome, an X-linked disorder that generally kills boys early in life while severely disrupting the lives of girls.
With the Alzheimer's Association International Conference underway in Washington, DC, there's been a big focus on the late-stage pipeline. But scientists at NYU Langone Medical Center were focused on new animal data that they say supports work on a new group of antibodies that can tackle two of the chief culprits behind the brain-damaging disease.
From Our Sister Sites
Former Allergan CEO David Pyott and activist investor Bill Ackman called each other plenty of things during last year's months-long Valeant-Allergan takeover battle. But Pyott had a new one during a Senate committee hearing on Thursday.
ResMed increased its focus on sleep disorder devices by acquiring China's Curative Medical for an undisclosed sum, in an attempt to gain a foothold in a fast-growing market.